🧪 DIPCOVAN: DRDO's Indigenous COVID-19 Antibody Detection Kit | A Breakthrough in Medical Technology:
DRDO has developed DIPCOVAN, an indigenous COVID-19 antibody detection kit designed to identify antibodies against the coronavirus. The innovation marks a significant achievement in India's healthcare and diagnostic technology sector.🦠🔬
✨ About the DIPCOVAN:
Defence Research and Development Organization (DRDO) of India has developed a COVID-19 antibody detection kit named 'DIPCOVAN'. It has been approved by the Indian Council of Medical Research and has been developed by the Defence Institute of Physiology and Allied Sciences lab of DRDO in association with Delhi’s Vanguard Diagnostics Pvt Ltd.
In May 2021, it received the regulatory approval of the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, for manufacture, sale, and distribution.
✨ Targeting 'SARS-CoV-2' Related Antigens:
'DIPCOVAN' is formed for the qualitative detection of IgG antibodies in human serum or plasma, targeting SARS-CoV-2 related antigens, which offers a significantly quick turnaround of just 75 minutes to conduct the test with no cross-reactivity with other diseases.
✨ Self Life Duration:
The kit features a time period of 18 months.
✨ Result Time & Cost:
It can give the end in 75 minutes and can cost Rs 75.
✨ High Sensitivity & specificity:
The DIPCOVAN kit can detect both spikes and nucleocapsid proteins of Coronavirus with a high sensitivity and specificity of 97% and 99%, respectively.
✨ Sample Size for the testing?
This kit was developed “indigenously by the scientists, followed by extensive validation on greater than 1,000 patient samples” at various Covid-designated hospitals in Delhi and was approved by the Indian Council of Medical Research (ICMR) in April,2021.
✨ Commercial Launch of The Product:
Vanguard Diagnostics would commercially launch the product in the first week of 2021.
✨ Who Unveiled the First Batch of It?
Defence Minister Rajnath Singh had unveiled the primary batch of DRDO’s 2-DG drug on May 17, 2021.
✨ Key Features of DIPCOVAN:
- 🧪 Antibody Detection – Detects the presence of antibodies developed against COVID-19.
- 🔬 Indigenously Developed – Designed and developed in India by the Defence Research and Development Organisation (DRDO).
- ⚡ Rapid Testing Capability – Helps assess immune response efficiently.
- 🏥 Useful for Sero-Surveillance – Supports studies aimed at understanding the spread of COVID-19 in populations.
- 📊 High Accuracy – Developed with a focus on reliable antibody detection.
- 🧪 Supports Self-Reliance – Strengthens India's indigenous healthcare and diagnostic ecosystem.
✍️ Final Thought:
The development of DIPCOVAN by DRDO highlights India's growing capabilities in healthcare innovation and diagnostic technology. By providing an indigenous solution for COVID-19 antibody detection, the kit contributes to disease surveillance, research, and public health efforts. This achievement reflects the country's commitment to scientific advancement and self-reliance in critical healthcare technologies.🏥✨
Also, Read:
*Black Fungus vs White Fungus vs Yellow Fungus | Symptoms, Causes & Key Differences Explained:
*Top 20 Facts About the Number Seven That are Purely Amazing:
*India’s Top 10 Hindu Temples – Most Famous & Sacred Temples in India:
*Top 15 Amazing Cryptocurrency Facts You Should Know:
*Cyclone Yaas Set to Impact West Bengal and Odisha | Weather Alert Issued:
*Do you know these top 20 amazing characteristics of a dog?
"Hello, readers, hope you enjoy this article. Let me know in the comment section how you find it, and also give your valuable suggestions. Thank you so much for the visit.